Show
Volume 79, Issue 4, 1 February 2022, Pages 390-414 https://doi.org/10.1016/j.jacc.2021.11.021Get rights and content hypertrophic cardiomyopathy ASA HCM hypertrophic cardiomyopathy ICD implantable cardioverter-defibrillator LGE late gadolinium enhancement NYHA New York Heart Association Volume 44, Issue 10, 16 November 2004, Pages 2044-2053 https://doi.org/10.1016/j.jacc.2004.04.063Get rights and content HCM hypertrophic cardiomyopathy
Top 10 Take-Home Messages–2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy e559 Preamble e560 1. Introduction e562 1.1. Methodology and Evidence Review e562 1.2. Organization of the Writing Committee e562 1.3. Document Review and Approval e563 1.4. Scope of the Guideline e563 1.5. Class of Recommendation and Level of Evidence e564 1.6. Abbreviations e564 2. Definition, Etiology, Clinical Course, and Natural History e564 2.1. Prevalence e564 2.2. Nomenclature/Differential Diagnosis e564 2.3. Definition, Clinical Diagnosis, and Phenotype e565 2.4. Etiology e565 2.5. Natural History/Clinical Course e566 3. Pathophysiology e566 3.1. LVOT Obstruction e566 3.2. Diastolic Dysfunction e567 3.3. Mitral Regurgitation e567 3.4. Myocardial Ischemia e567 3.5. Autonomic Dysfunction e567 4. Shared Decision-Making e568 5. Multidisciplinary HCM Centers e569 6. Diagnosis, Initial Evaluation, and Follow-up e570 6.1. Clinical Diagnosis e570 6.2. Echocardiography e571 6.3. Cardiovascular Magnetic Resonance Imaging e574 6.4. Cardiac Computed Tomography e576 6.5. Heart Rhythm Assessment e576 6.6. Angiography and Invasive Hemodynamic Assessment e577 6.7. Exercise Stress Testing e578 6.8. Genetics and Family Screening e579 6.9. Genotype-Positive, Phenotype-Negative e583 7. SCD Risk Assessment and Prevention e584 7.1. SCD Risk Assessment e584 7.2. Patient Selection for ICD Placement e586 7.3. Device Selection Considerations e588 8. Management of HCM e590 8.1. Management of Symptomatic Patients With Obstructive HCM e590 8.1.1. Pharmacologic Management of Symptomatic Patients With Obstructive HCM e590 8.1.2. Invasive Treatment of Symptomatic Patients With Obstructive HCM e591 8.2. Management of Patients With Nonobstructive HCM With Preserved EF e593 8.3. Management of Patients With HCM and Atrial Fibrillation e595 8.4. Management of Patients With HCM and Ventricular Arrhythmias e597 8.5. Management of Patients With HCM and Advanced HF e599 9. Lifestyle Considerations for Patients With HCM e602 9.1. Sports and Activity e602 9.2. Occupation e604 9.3. Pregnancy e605 9.4. Comorbidities e606 10. Unmet Needs e607 10.1. Limitations and Knowledge Gaps e607 10.1.1. Clinical Trials e607 10.1.2. Prevent or Attenuate Disease Progression e607 10.1.3. Reduce Symptom Burden and Increase Functional Capacity, Particularly in Nonobstructive HCM e607 10.1.4. Risk Stratification e607 10.1.5. Arrhythmia Management e607 10.1.6. Genetics e608 10.1.7. Exercise and Sports Participation e608 References e609 Appendix 1. Author Relationships With Industry and Other Entities (Relevant) e626 Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive) e628 Shared decision-making, a dialogue between patients and their care team that includes full disclosure of all testing and treatment options, discussion of the risks and benefits of those options and, importantly, engagement of the patient to express their own goals, is particularly relevant in the management of conditions such as hypertrophic cardiomyopathy (HCM). Although the primary cardiology team can initiate evaluation, treatment, and longitudinal care, referral to multidisciplinary HCM centers with graduated levels of expertise can be important to optimizing care for patients with HCM. Challenging treatment decisions—where reasonable alternatives exist, where the strength of recommendation is weak (eg, any Class 2b decision) or is particularly nuanced, and for invasive procedures that are specific to patients with HCM—represent crucial opportunities to refer patients to these HCM centers. Counseling patients with HCM regarding the potential for genetic transmission of HCM is one of the cornerstones of care. Screening first-degree family members of patients with HCM, using either genetic testing or an imaging/electrocardiographic surveillance protocol, can begin at any age and can be influenced by specifics of the patient/family history and family preference. As screening recommendations for family members hinge on the pathogenicity of any detected variants, the reported pathogenicity should be reconfirmed every 2 to 3 years. Optimal care for patients with HCM requires cardiac imaging to confirm the diagnosis, characterize the pathophysiology for the individual, and identify risk markers that may inform decisions regarding interventions for left ventricular outflow tract obstruction and sudden cardiac death (SCD) prevention. Echocardiography continues to be the foundational imaging modality for patients with HCM. Cardiovascular magnetic resonance imaging will also be helpful in many patients, especially those in whom there is diagnostic uncertainty, poor echocardiographic imaging windows, or where uncertainty persists regarding decisions around implantable cardioverter-defibrillator (ICD) placement. Assessment of an individual patient’s risk for SCD continues to evolve as new markers emerge (eg, apical aneurysm, decreased left ventricular systolic function, and extensive gadolinium enhancement). In addition to a full accounting of an individual’s risk markers, communication with patients regarding not just the presence of risk markers but also the magnitude of their individualized risk is key. This enables the informed patient to fully participate in the decision-making regarding ICD placement, which incorporates their own level of risk tolerance and treatment goals. The risk factors for SCD in children with HCM carry different weights than those observed in adult patients; they vary with age and must account for different body sizes. Coupled with the complexity of placing ICDs in young patients with anticipated growth and a higher risk of device complications, the threshold for ICD implantation in children often differs from adults. These differences are best addressed at primary or comprehensive HCM centers with expertise in children with HCM. Septal reduction therapies (surgical septal myectomy and alcohol septal ablation), when performed by experienced HCM teams at dedicated centers, continue to improve in safety and efficacy such that earlier intervention may be possible in select patients with drug-refractory or severe outflow tract obstruction causing signs of cardiac decompensation. Given the data on the significantly improved outcomes at comprehensive HCM centers, these decisions represent an optimal referral opportunity. Patients with HCM and persistent or paroxysmal atrial fibrillation have a sufficiently increased risk of stroke such that oral anticoagulation with direct oral anticoagulants (or alternatively warfarin) should be considered the default treatment option independent of the CHA2DS2VASc score. As rapid atrial fibrillation is often poorly tolerated in patients with HCM, maintenance of sinus rhythm and rate control are key pursuits in successful treatment. Heart failure symptoms in patients with HCM, in the absence of left ventricular outflow tract obstruction, should be treated similarly to other patients with heart failure symptoms, including consideration of advanced treatment options (eg, cardiac resynchronization therapy, left ventricular assist device, transplantation). In patients with HCM, an ejection fraction <50% connotes significantly impaired systolic function and identifies individuals with poor prognosis and who are at increased risk for SCD. Increasingly, data affirm that the beneficial effects of exercise on general health can be extended to patients with HCM. Healthy recreational exercise (moderate intensity) has not been associated with increased risk of ventricular arrhythmia events in recent studies. Whether an individual patient with HCM wishes to pursue more rigorous exercise/training is dependent on a comprehensive shared discussion between that patient and their expert HCM care team regarding the potential risks of that level of training/participation but with the understanding that exercise-related risk cannot be individualized for a given patient. Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a foundation for the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and publication of clinical practice guidelines without commercial support, and members volunteer their time to the writing and review efforts. Guidelines are official policy of the ACC and AHA. For some guidelines, the ACC and AHA partner with other organizations. Intended UseClinical practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but these guidelines are relevant to patients throughout the world. Although guidelines may be used to inform regulatory or payer decisions, the intent is to improve quality of care and align with patients’ interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances and should not replace clinical judgment. Clinical ImplementationManagement, in accordance with guideline recommendations, is effective only when followed by both practitioners and patients. Adherence to recommendations can be enhanced by shared decision-making between clinicians and patients, with patient engagement in selecting interventions on the basis of individual values, preferences, and associated conditions and comorbidities. Methodology and ModernizationThe ACC/AHA Joint Committee on Clinical Practice Guidelines (Joint Committee) continuously reviews, updates, and modifies guideline methodology on the basis of published standards from organizations, including the Institute of Medicine,1,2 and on the basis of internal reevaluation. Similarly, presentation and delivery of guidelines are reevaluated and modified in response to evolving technologies and other factors to optimally facilitate dissemination of information to healthcare professionals at the point of care. Numerous modifications to the guidelines have been implemented to make them shorter and enhance “user friendliness.” Guidelines are written and presented in a modular, “knowledge chunk” format, in which each chunk includes a table of recommendations, a brief synopsis, recommendation-specific supportive text and, when appropriate, flow diagrams or additional tables. Hyperlinked references are provided for each modular knowledge chunk to facilitate quick access and review. In recognition of the importance of cost–value considerations, in certain guidelines, when appropriate and feasible, an analysis of value for a drug, device, or intervention may be performed in accordance with the ACC/AHA methodology.3 To ensure that guideline recommendations remain current, new data will be reviewed on an ongoing basis by the writing committee and staff. Going forward, targeted sections/knowledge chunks will be revised dynamically after publication and timely peer review of potentially practice-changing science. The previous designations of “full revision” and “focused update” will be phased out. For additional information and policies on guideline development, readers may consult the ACC/AHA guideline methodology manual4 and other methodology articles.5–7 Selection of Writing Committee MembersThe Joint Committee strives to ensure that the guideline writing committee contains requisite content expertise and is representative of the broader cardiovascular community by selection of experts across a spectrum of backgrounds, representing different geographic regions, sexes, races, ethnicities, intellectual perspectives/biases, and clinical practice settings. Organizations and professional societies with related interests and expertise are invited to participate as partners or collaborators. Relationships With Industry and Other EntitiesThe ACC and AHA have rigorous policies and methods to ensure that documents are developed without bias or improper influence. The complete policy on relationships with industry and other entities (RWI) can be found at https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy. Appendix 1 of the guideline lists writing committee members’ relevant RWI; for the purposes of full transparency, their comprehensive disclosure information is available online. Comprehensive disclosure information for the Joint Committee is also available at https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-task-forces. Evidence Review and Evidence Review CommitteesIn developing recommendations, the writing committee uses evidence-based methodologies that are based on all available data.4–5 Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only key references are cited. An independent evidence review committee is commissioned when there are ≥1 questions deemed of utmost clinical importance and merit formal systematic review to determine which patients are most likely to benefit from a drug, device, or treatment strategy, and to what degree. Criteria for commissioning an evidence review committee and formal systematic review include absence of a current authoritative systematic review, feasibility of defining the benefit and risk in a time frame consistent with the writing of a guideline, relevance to a substantial number of patients, and likelihood that the findings can be translated into actionable recommendations. Evidence review committee members may include methodologists, epidemiologists, clinicians, and biostatisticians. Recommendations developed by the writing committee on the basis of the systematic review are marked “SR.” Guideline-Directed Management and TherapyThe term guideline-directed management and therapy (GDMT) encompasses clinical evaluation, diagnostic testing, and both pharmacological and procedural treatments. For these and all recommended drug treatment regimens, the reader should confirm dosage with product insert material and evaluate for contraindications and interactions. Recommendations are limited to drugs, devices, and treatments approved for clinical use in the United States. Patrick T. O’Gara, MD, MACC, FAHA Chair, ACC/AHA Joint Committee on Clinical Practice Guidelines 1. Introduction1.1. Methodology and Evidence ReviewThe recommendations listed in this guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline, was conducted from January 1, 2010, to April 30, 2020. Key search words included but were not limited to the following: hypertrophic cardiomyopathy, coronary, ischemia, systole, atrial fibrillation, exercise, stroke volume, transplant, magnetic resonance imaging, sudden death, sudden cardiac death, left ventricular hypertrophy, subvalvular stenosis, echocardiography, nuclear magnetic resonance imaging, computed tomographic angiography, genetic testing, and diagnostic imaging. Additional relevant studies, published through April 2020 during the guideline writing process, were also considered by the writing committee and added to the evidence tables when appropriate. The final evidence tables are included in the Online Data Supplement and summarize the evidence used by the writing committee to formulate recommendations. References selected and published in the present document are representative and not all-inclusive. 1.2. Organization of the Writing CommitteeThe writing committee consisted of clinicians, cardiologists, interventionalists, cardiovascular surgeons, and a lay/patient representative. The writing committee included representatives from the ACC, AHA, American Association for Thoracic Surgery, American Society of Echocardiography, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Appendix 1 lists writing committee members’ relevant RWI. For the purposes of full transparency, the writing committee members’ comprehensive disclosure information is available online. 1.3. Document Review and ApprovalThis document was reviewed by 2 official reviewers each nominated by the ACC and AHA, 1 reviewer each from the American Association for Thoracic Surgery, American Society of Echocardiography, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance, and 26 individual content reviewers. Reviewers’ RWI information was distributed to the writing committee and is published in this document (Appendix 2). This document was approved for publication by the governing bodies of the ACC and the AHA and was endorsed by all collaborators and The Pediatric & Congenital Electrophysiology Society. 1.4. Scope of the GuidelineThe purpose of this new guideline is to commission a full guideline revision of the previous “2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy.”1 The current version will replace the 2011 guideline and addresses comprehensive evaluation and management of adults and children with hypertrophic cardiomyopathy (HCM). Diagnostic modalities such as electrocardiography, imaging and genetic testing, and management of patients include medical therapies, septal reduction therapies, sudden cardiac death (SCD) risk assessment/prevention, and lifestyle considerations such as participation in activities/sports, occupation, and pregnancy. Table 1 lists other guidelines and pertinent documents that the writing committee considered for this guideline. The listed documents contain relevant information for the management of patients with hypertrophic cardiomyopathy.
1.5. Class of Recommendation and Level of EvidenceThe Class of Recommendation (COR) indicates the strength of recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates the quality of scientific evidence supporting the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table 2).1
1.6. Abbreviations2. Definition, Etiology, Clinical Course, and Natural History2.1. PrevalenceHCM is a common genetic heart disease reported in populations globally. Inherited in an autosomal dominant pattern, the distribution of HCM is equal by sex, although women are diagnosed less commonly than men. The prevalence of HCM depends on whether subclinical or clinically evident cases are being considered, is age dependent, and may have racial/ethnic differences.1 The prevalence of unexplained asymptomatic hypertrophy in young adults in the United States has been reported to range from 1:200 to 1:500.2 Symptomatic hypertrophy based on medical claims data has been estimated at <1:3000 adults in the United States; however, the true burden is much higher when unrecognized disease in the general population is considered.3 Clinical evaluation for HCM may be triggered by occurrence of symptoms, a cardiac event, detection of a heart murmur, an abnormal 12-lead ECG identified on routine examination, or through cardiac imaging during family screening studies. 2.2. Nomenclature/Differential DiagnosisSince the original clinical description of HCM >60 years ago, various names have been used to describe this disease, including idiopathic hypertrophic subaortic stenosis and hypertrophic obstructive cardiomyopathy. Because left ventricular (LV) outflow tract obstruction (LVOTO) is present or develops over time in most patients with HCM, yet one-third remain nonobstructive, the writing committee recommends the term HCM (with or without outflow tract obstruction). In some areas, the use of HCM to describe the increased LV wall thickness associated with systemic disorders or secondary causes of LV hypertrophy (LVH) can lead to confusion. Systemic disorders include various metabolic and multiorgan syndromes such as RASopathies (variants in several genes involved in RAS-MAPK signaling), mitochondrial myopathies, glycogen/lysosomal storage diseases in children, and Fabry, amyloid, sarcoid, hemochromatosis, Danon cardiomyopathy in adults. In these diseases, although the magnitude and distribution of increased LV wall thickness can be similar to that of isolated HCM caused by variants in sarcomeric genes, the pathophysiologic mechanisms responsible for hypertrophy, natural history, and treatment strategies are not the same.1–5 For these reasons, other cardiac or systemic diseases capable of producing LVH should not be labeled as HCM and will not be addressed in this document. In addition, other scenarios can arise that present diagnostic challenges, including conditions that produce secondary LVH, which can also overlap phenotypically with HCM, including remodeling secondary to athletic training (ie, “athletes heart”) as well as morphologic changes related to long-standing systemic hypertension (ie, hypertensive cardiomyopathy). Similarly, hemodynamic obstruction caused by left-sided obstructive lesions (valvular or subvalvular stenosis) or obstruction after antero-apical infarction and stress cardiomyopathy can cause diagnostic dilemmas.6,7 Although HCM cannot be definitely excluded in such situations, a number of clinical markers and testing strategies can be used to help differentiate between HCM and conditions of physiologic LVH. 2.3. Definition, Clinical Diagnosis, and PhenotypeFor the purposes of this guideline, we have considered the clinical definition of HCM as a disease state in which morphologic expression is confined solely to the heart. It is characterized predominantly by LVH in the absence of another cardiac, systemic, or metabolic disease capable of producing the magnitude of hypertrophy evident in a given patient and for which a disease-causing sarcomere (or sarcomere-related) variant is identified, or genetic etiology remains unresolved. A clinical diagnosis of HCM in adult patients can therefore be established by imaging (Section 6.1), with 2D echocardiography or cardiovascular magnetic resonance (CMR) showing a maximal end-diastolic wall thickness of ≥15 mm anywhere in the left ventricle, in the absence of another cause of hypertrophy in adults.1–4 More limited hypertrophy (13–14 mm) can be diagnostic when present in family members of a patient with HCM or in conjunction with a positive genetic test. For children, the diagnostic criteria are confounded by needing to adjust for body size and growth. Traditionally, a body surface area adjusted z-score of ≥2 standard deviations above the mean has been used. This cut-off represents a significantly lower threshold than the 15-mm absolute value used in adults. For reference, 15 mm represents a z-score of approximately 6 standard deviations above the mean in adults. We propose that the diagnosis of HCM in children should therefore consider the circumstances of screening and the pretest probability of disease: a threshold of z >2.5 may be appropriate to identify early HCM in asymptomatic children with no family history, whereas for children with a definitive family history or a positive genetic test, a threshold of z >2 may suffice for early diagnosis. The emergence of the HCM phenotype in younger family members who carry a pathogenic sarcomere variant without previously evident LVH at initial screening (ie, genotype-positive/previously phenotype-negative) is well recognized and underscores the principle that normal or mildly increased LV wall thicknesses will be encountered in individuals with genetically affected status, as the disease manifests. In the absence of increased wall thickness, such individuals should be considered at risk for subsequent development of, but not yet having, clinically evident HCM. Nearly any pattern and distribution of LV wall thickening can be observed in HCM, with the basal anterior septum in continuity with the anterior free wall the most common location for LVH. In a subset of patients, hypertrophy can be limited and focal, confined to only 1 or 2 LV segments with normal LV mass. Although common in HCM, neither systolic anterior motion (SAM) of the mitral valve nor hyperdynamic LV function is required for a clinical diagnosis. A number of other morphologic abnormalities are also not diagnostic of HCM but can be part of the phenotypic expression of the disease, including hypertrophied and apically displaced papillary muscles, myocardial crypts, anomalous insertion of the papillary muscle directly in the anterior leaflet of the mitral valve (in the absence of chordae tendinae), elongated mitral valve leaflets, myocardial bridging, and right ventricular (RV) hypertrophy. 2.4. EtiologyIn the early 1990s, the DNA sequencing of HCM pedigrees led to the discovery that damaging variants in genes coding for sarcomere proteins segregated (or were co-inherited) with LVH identified by echocardiographic assessment, abnormal ECGs, and physical findings. HCM thereby became regarded as a monogenic cardiac disease, helping to consolidate a clinically heterogeneous disease into a single entity based on genetic substrate.1 Currently, variants in 1 of 8 or more genes encoding proteins of the cardiac sarcomere (or sarcomere-related structures) have been implicated in causing LVH, the sine qua non of HCM. Among patients with HCM, ~30% to 60% have an identifiable pathogenic or likely pathogenic genetic variant. A substantial proportion of patients with HCM are currently without any evidence of a genetic etiology to their disease, including a subgroup (up to 40% of patients in 1 study) who also have no other affected family members (ie, “non-familial” HCM).2 These observations suggest that other novel pathophysiologic mechanisms may be responsible or contribute to phenotypic expression in these affected patients with HCM. Among patients with HCM and a pathogenic sarcomeric gene variant, the 2 most common genes are beta myosin heavy chain 7 (MYH7) and myosin-binding protein C3 (MYBPC3), identified in 70% of variant-positive patients, while other genes (TNNI3, TNNT2, TPM1, MYL2, MYL3, ACTC1) each account for a small proportion of patients (1% to 5%). Within these genes, >1500 variants have been recognized, the majority of which are “private” (unique to the individual family). Each offspring of an affected family member has a 50% chance of inheriting the variant.3 Although the likelihood of developing clinical HCM is high in family members with a pathogenic variant, the age at which disease expression occurs in a given individual is variable. The precise mechanisms by which sarcomere variants result in the clinical phenotype have not been fully elucidated. Mutant sarcomere genes trigger myocardial changes, leading to hypertrophy and fibrosis, which ultimately results in a small, stiff ventricle with impaired systolic and diastolic performance despite a preserved LVEF. Similarly, abnormal sarcomeric proteins may not be solely responsible for all of the clinical characteristics observed in patients with HCM. Diverse disease features including abnormal intramural coronary arteries responsible for small vessel ischemia, elongated mitral valve leaflets, and congenital anomalies of the sub-mitral valve apparatus, which are widely recognized components of the HCM phenotype, appear to have no known direct association with sarcomere variants. 2.5. Natural History/Clinical CourseAlthough HCM can be compatible with normal life expectancy without limiting symptoms or the need for major treatments in most patients, other patients can experience significant consequences that are attributable to the disease. To this point, there is increasing recognition of patients with HCM identified clinically at advanced ages of >60 years with little to no disability. Yet, a multicenter registry report has suggested that the lifelong risk of adverse events (eg, mortality, HF, stroke, ventricular arrhythmia, AF) caused by HCM may be greater among patients with pathogenic sarcomeric gene variants or those diagnosed early in life.1 The large number and diversity of the HCM-associated variants does not allow the specific genotype to be used to inform the anticipated outcomes in individual patients. Among referral-based cohorts of patients with HCM, 30% to 40% will experience adverse events, including: 1) sudden death events; 2) progressive limiting symptoms because of LVOTO or diastolic dysfunction; 3) HF symptoms associated with systolic dysfunction; and 4) AF with risk of thromboembolic stroke. Nevertheless, studies reporting relatively long-term HCM patient outcomes have demonstrated that for patients at risk for, or who develop one of these, disease-related complications, the application of contemporary cardiovascular therapies and interventions has lowered HCM mortality rates to <1.0%/year.2,3 One of the major treatment initiatives responsible for lowering mortality has been the evolution of SCD risk stratification strategies based on a number of major noninvasive risk markers, which can identify adult patients with HCM at greatest risk for sudden death who are then candidates for implantable cardioverter-defibrillator (ICD) placement. The decrease in sudden death rates in HCM appears now to have shifted focus to heart failure (HF) as the predominant cause of disease-related morbidity and mortality and, therefore, greatest unmet treatment need in adults. 3. PathophysiologyThe pathophysiology of HCM consists of dynamic LVOTO, mitral regurgitation (MR), diastolic dysfunction, myocardial ischemia, arrhythmias, and autonomic dysfunction. For a given patient with HCM, the clinical outcome may be dominated by one of these components or may be the result of a complex interplay. Thus, it is prudent to consider the potential presence of such abnormalities in a comprehensive clinical evaluation and address their impact in the management of these patients. 3.1. LVOT ObstructionLVOTO, either at rest or with provocation, is present in ~75% of patients with HCM.1 Two principal mechanisms are responsible for LVOTO: 1) septal hypertrophy with narrowing of the LVOT, leading to abnormal blood flow vectors that dynamically displace the mitral valve leaflets anteriorly; and 2) anatomic alterations in the mitral valve and apparatus, including longer leaflets as well as anterior displacement of the papillary muscles and mitral valve apparatus, which makes the valve more susceptible to the abnormal flow vectors. Consequently, there is systolic anterior motion of the mitral valve leaflets, which leads to LVOTO, high intracavitary pressures, and MR from the loss of leaflet coaptation.2–5 By causing increased LV systolic pressure, LVOTO also may exacerbate LVH, myocardial ischemia, and prolong ventricular relaxation. LVOTO is associated with impaired stroke volume and an increased risk of HF and poorer survival.6,7 The presence of a peak LVOT gradient of ≥30 mm Hg is considered to be indicative of obstruction, with resting or provoked gradients ≥50 mm Hg generally considered to be the threshold for septal reduction therapy (SRT) in those patients with drug-refractory symptoms. LVOTO in HCM is dynamic and sensitive to ventricular load and contractility.8 Increased myocardial contractility, decreased preload, or lower afterload will increase the LVOT gradient. Subtle changes in these conditions may be noted and can lead to large variations in LVOT gradients and obstruction. Spontaneous variability in the LVOT gradient can occur with daily activities, food and alcohol intake, or even with quiet respiration.9,10 Thus, provocative maneuvers may be necessary in patients with low or absent peak resting gradients (ie, <30 mm Hg) to elicit the presence of LVOTO, particularly in patients with symptoms. Such maneuvers include standing, Valsalva strain, amyl nitrite inhalation, or exercise (fasted or postprandial), with simultaneous echocardiography performed to document the relation of the gradient to occurrence of systolic anterior motion of the mitral valve11–15 Because of the lack of specificity, the use of dobutamine for determination of provocative LVOTO and eligibility for SRT is not advised.16 The diagnosis of LVOTO is made most commonly with echocardiography and, in some experienced centers (Table 3), with CMR imaging when echocardiographic imaging is suboptimal. The site and characteristics of the obstruction should be located, such as valvular, dynamic LVOTO, fixed subvalvular, midcavitary gradients associated with hypertrophied papillary muscles, anomalous papillary muscle insertion, or muscular obstruction caused by compensatory mid-ventricular hyperkinesis after apical infarction. In some instances, there is discordant information between the clinical findings and echocardiography in a symptomatic patient in whom SRT is being contemplated. Invasive assessment for LVOTO may be helpful in these circumstances.17
3.2. Diastolic DysfunctionAltered ventricular load with high intracavitary pressures, nonuniformity in ventricular contraction and relaxation, and delayed inactivation from abnormal intracellular calcium reuptake are common abnormalities in HCM, and each contribute to the presence of diastolic dysfunction.1–3 Chamber stiffness can arise from myocardial hypertrophy, ischemia, and replacement or interstitial fibrosis. In some patients, the severity of hypertrophy also significantly compromises ventricular cavity size and stroke volume. Altered systolic-diastolic coupling and impaired cardiac cellular energetics are also causes of decreased exercise capacity in HCM, which carries prognostic impact independent of LVOTO.2,4,5 CMR imaging with late gadolinium-enhancement (LGE) can be used to detect and quantify myocardial fibrosis and scarring, which contributes to diastolic dysfunction as well as future left ventricular remodeling.6,7 Finally, an association between left atrial fibrosis, HCM, and atrial fibrillation (AF) has been reported.8 Exercise intolerance or symptoms of HF can occur from diastolic dysfunction in the absence of LVOTO and may require invasive testing with or without exercise testing to detect. With impairment in ventricular myocardial relaxation, greater dependency on the atrial systole for ventricular filling may occur, leading to poor tolerance of AF or similar arrhythmias in some patients. 3.3. Mitral RegurgitationMitral regurgitation (MR) can occur secondarily from LVOTO or from primary leaflet abnormalities and contributes to symptoms of dyspnea. In MR caused by LVOTO, SAM of the mitral valve leads to loss of leaflet coaptation, and the jet is predominantly mid-to-late systolic and posterior or lateral in orientation.1 A posteriorly directed jet of MR in obstructive HCM correlates with SAM of the mitral valve as the underlying pathophysiologic mechanism. However, central and anterior jets may also result from SAM of the mitral valve (ie, these jets do not reliably predict primary mitral leaflet abnormalities), and caution is necessary in using the jet direction of MR on preoperative transthoracic echocardiogram (TTE) to guide the decision for concomitant mitral valve surgery during septal myectomy for HCM. Factors that affect the severity of LVOTO also may affect the degree of MR. Thus, significant MR may not be evident without provocation for LVOTO and SAM of the mitral valve. Primary abnormalities of the mitral valve and its apparatus are also common, including excessive leaflet length, anomalous papillary muscle insertion, and anteriorly displaced papillary muscles.2–4 In some patients, these primary mitral valve abnormalities may be the principal cause of symptoms. For patients in whom SRT is being contemplated, close examination for mitral valve abnormalities should be performed to determine the optimal invasive approach.5,6 3.4. Myocardial IschemiaPatients with HCM are susceptible to myocardial ischemia attributable to a mismatch between myocardial oxygen supply and demand. Myocardial hypertrophy, microvascular dysfunction with impaired coronary flow reserve, and medial hypertrophy of the intramural arterioles and their reduced density are common findings.1,2 These abnormalities are worsened by the presence of hyperdynamic systolic function and LVOTO with high intracavitary pressures.3,4 Blunted coronary flow reserve occurs even without epicardial stenosis, although the presence of concomitant severe coronary atherosclerosis exacerbates mismatch and is associated with a poorer prognosis.5 The presence of myocardial ischemia may lead to infarction, which may be evident as LGE on CMR imaging.6 Apical myocardial ischemia and infarction (with or without midventricular obstruction) may be one of the mechanisms that contributes to the development of LV aneurysms, which carry increased risk of HF and ventricular arrhythmias.7,8 Myocardial bridging, a congenital anomaly whereby a bridge of overlying myocardium causes systolic compression of an epicardial coronary artery that can persist into diastole, may impair blood flow and is a rare cause of myocardial ischemia in a subset of patients.9–13 3.5. Autonomic DysfunctionPatients with HCM can have autonomic dysfunction, with impaired heart rate recovery and inappropriate vasodilatation.1–4 The prevalence of autonomic dysfunction in HCM is uncertain, although studies have described an abnormal blood pressure response to exercise in ~25% of patients.2–4 An abnormal blood pressure response to exercise, defined as failure to increase systolic blood pressure by at least 20 mm Hg, or a drop in systolic blood pressure during exercise of >20 mm Hg from the peak value obtained, has been associated with a poorer prognosis. However, this blood pressure response may be attributable to autonomics, diastolic filling abnormalities, or LVOTO. This implies that the abnormal blood pressure response may be modifiable with medical and surgical therapy. 4. Shared Decision-MakingSynopsis Shared decision-making is a dialogue that allows patients and providers to work together to select options that fully consider the input, values, and preferences of the patient (or their families in the case of an affected minor). This approach has been shown to improve confidence in clinical decisions and improved health outcomes.7 Although shared decision discussions should be the default interaction between patients (or their families in the case of an affected minor) and their care teams, the biggest opportunities are those areas where there are complex pathways that vary by the individual patient. In the management of HCM, decisions around genetic testing, ICD implantation, invasive therapies for relief of LVOTO, and participation in competitive or high-intensity exercise are particularly ripe for these crucial dialogues. Some of these discussions and decisions could also represent opportunities where referral to centers with more comprehensive experience are most appropriate and highly impactful. 5. Multidisciplinary HCM CentersSynopsis The specialized needs, complex and evolving clinical management, and the relatively uncommon prevalence of HCM in many clinical practices have created a greater demand and need for clinical HCM centers with HCM-specific competencies similar to that proposed for the management of patients with valvular heart disease.5–7,14 These competencies often require specialized training and sufficient volumes to maintain desired outcomes. The main goal of the HCM centers’ framework is to optimize care and counseling of patients with HCM and their families. It is recognized that care necessarily involves healthcare teams whose expertise falls along a spectrum rather than as a binary (present/absent) condition. The proposed approach recognizes that spectrum and is inclusive of roles for cardiologists working outside of HCM centers, those working in primary HCM centers that offer many or most HCM-specific services, and those working at fully comprehensive HCM centers. Participation in quality assessment and research to advance the understanding of HCM also falls more squarely in the realm of the HCM centers. Cardiologists practicing outside of HCM centers have a critical role in many aspects of HCM management (Table 3) including, but not limited to, providing ready access for initial and surveillance testing, treatment recommendations, and availability for rapid assessment when a patient’s disease course changes. Referral to HCM centers can help to confirm diagnosis, provide genetic counseling and testing, advise regarding more advanced treatment decisions, and provide patients with access to the highest level of longitudinal care possible for their disease.7 It is the expectation that primary and comprehensive HCM centers provide direct communication along established referral lines between programs themselves as well as the community of referring providers/centers in an effort to improve the quality of care in all settings and meet the needs of the individual patient. A dedicated, multidisciplinary primary HCM center should be composed of a team with a high level of competence in treating patients with HCM, including the skills suggested in Table 3. Primary HCM centers that perform invasive SRTs should ensure reasonable outcomes for safety and benefit, commensurate with that reported from comprehensive HCM centers (Table 3 and Table 4). If only one of the invasive SRT options is available at a given center, patients should be fully informed of alternative options, including the pros and cons of both procedures and the possibility for referral to a comprehensive center that offers all treatment options to ensure appropriate patient participation in the decision-making.
A comprehensive HCM center comprises a similar organizational structure as a primary HCM center but has demonstrated graduated levels of expertise and resources specific for HCM that include additional competencies (Table 3). Referral to a comprehensive HCM center should specifically be considered for those patients with HCM who are candidates for any procedure specific to, or which requires specialized expertise to perform in, HCM, including particularly complex invasive SRTs,3,8,9 catheter ablation for ventricular and complex atrial tachyarrhythmias,10,11 and advanced HF therapies, including transplant.12,13 In addition, referral to a comprehensive HCM center can aid in complex disease-related management decisions including, but not limited to, particularly challenging primary prevention ICD decision-making as well as counseling patients with HCM on the potential risks associated with participating in competitive sports.4 Recommendation-Specific Supportive Text
6. Diagnosis, Initial Evaluation, and Follow-up6.1. Clinical DiagnosisSynopsis Clinical evaluation for HCM may be triggered by the identification of a family history of HCM, symptoms including a cardiac event, a heart murmur during physical examination, during echocardiography performed for other indications, or an abnormal 12-lead ECG. A proper clinical evaluation should start with a comprehensive cardiac history, a family history including 3 generations, and a comprehensive physical examination (including maneuvers such as Valsalva, squat-to-stand, passive leg raising, or walking). This should be followed by an ECG and cardiac imaging to identify LVH when clinical findings are suggestive. Recommendation-Specific Supportive Text 1. Many patients with HCM are asymptomatic and identified incidentally or as a result of screening. Clinical history includes a detailed cardiac history and family history (3 generations) to identify relatives with HCM or with unexpected/sudden death. Assessment of overall fitness and functional capacity, with emphasis on training regimen and symptoms in response to exertion—chest pain, dyspnea, palpitations, and syncope. Associated syndromic or systemic/extracardiac symptoms or organ involvement are also documented (eg, ataxia, hearing, visual, or cognitive impairment, failure to thrive, neurodevelopmental abnormalities). Alternative etiologies to be considered include physiologic remodeling of the athlete, long-standing systemic hypertension, renal disease, or infiltrative diseases (amyloid cardiomyopathy). In neonates, a history of maternal gestational diabetes is sought, and in infants <1 year of age, a systemic disease is important to exclude. Table 5 lists other causes of LVH that may mimic HCM but are not the subject of this guideline.
Classically, patients with HCM have a systolic murmur, prominent apical point of maximal impulse, abnormal carotid pulse, and a fourth heart sound. SAM of the mitral valve leads to LVOTO and resultant harsh crescendo-decrescendo systolic murmur best heard over the lower left sternal border. Physical findings of outflow tract obstruction should be sought both at rest and with provocative maneuvers (Valsalva maneuver, standing from the squatting position), although this may not be feasible in young children. SAM related to an elongated anterior mitral valve leaflet and papillary muscle abnormalities may result in leaflet separation/poor coaptation with posteriorly directed mitral regurgitation in late systole over the mitral position. A prominent point of maximal impulse is usually present, shifted laterally and either bifid or trifid. A carotid double pulsation, known as pulsus bisferiens, and an S4 from a noncompliant left ventricle may be present. Those without LVOTO (provocable or resting) may have a normal physical examination. 6.2. EchocardiographySynopsis Cardiac imaging plays an essential role in diagnosis and clinical decision-making for patients with HCM. Echocardiography is the primary imaging modality in most patients, with CMR imaging offering complementary information and as an alternative to echocardiography for selected patients in whom the echocardiogram is inconclusive. Important information to be gained from imaging includes establishing the diagnosis (or excluding alternative diagnoses), evaluating the severity of the phenotype, and evaluating for concomitant structural and functional cardiac abnormalities (eg, systolic, diastolic, valvular function). Characterization of dynamic LVOTO, including the integral role of the mitral valve, is a key strength of echocardiography. Documentation of the maximal wall thickness, cardiac chamber dimensions, systolic function, and the presence of LV apical aneurysm all inform phenotype severity and SCD risk stratification. Recommendation-Specific Supportive Text
6.3. Cardiovascular Magnetic Resonance ImagingFigure 1. Recommended evaluation and testing for HCM. Colors correspond to the Class of Recommendation in Table 2. *The interval may be extended, particularly in adult patients who remain stable after multiple evaluations. CMR indicates cardiovascular magnetic resonance; CPET, cardiopulmonary exercise test; ECG, electrocardiography/electrocardiogram; HCM, hypertrophic cardiomyopathy; HF, heart failure; ICD, implantable cardioverter-defibrillator; LVOTO, left ventricular outflow tract obstruction; P/LP, pathogenic or likely pathogenic variant; SCD, sudden cardiac death; and VUS, variant of unknown significance. Synopsis CMR imaging provides high spatial resolution and fully tomographic imaging of the heart, as well as assessment of myocardial fibrosis after injection of contrast with LGE.1,2 These attributes of CMR imaging are well-suited for characterizing the diverse phenotypic expressions of HCM, providing diagnosis, risk prediction, and preprocedural planning for septal reduction.1,7 For these reasons, CMR imaging is an important complementary imaging technique in the evaluation of patients with HCM. CMR imaging has the distinct advantage, by virtue of producing images with sharp contrast between the blood pool and myocardium, to provide highly accurate LV wall thickness measurements, robust quantification of LV and RV chamber size, LV mass, systolic function, and can identify areas of LVH not well visualized by echocardiography.1–7 CMR imaging has also expanded our appreciation for the diversity in morphologic abnormalities, including LV apical aneurysms as well as structural abnormalities of the mitral valve and subvalvular apparatus that contribute to LVOTO, findings which may impact management strategies.7–9,16–19 Additionally, extensive LGE (ie, myocardial fibrosis) represents a noninvasive marker for increased risk for potentially life-threatening ventricular tachyarrhythmias and HF progression with systolic dysfunction.11–14 It is recognized that CMR imaging may not be feasible in certain patients because of availability, cost, contraindications attributable to pacemakers or ICDs, severe renal insufficiency, and patient factors (pediatric age and a requirement for general anesthesia, or sedation, claustrophobia, or body habitus). Recommendation-Specific Supportive Text
6.4. Cardiac Computed TomographySynopsis Cardiac CT provides excellent spatial resolution allowing for clear definition of LV structure (including hypertrophy pattern, wall thickness measurement, detection of subaortic membrane and intracardiac thrombus) and function. Small studies have demonstrated ability of CT to assess myocardial fibrosis, although this adds further radiation exposure and needs further validation. In addition to myocardial structure, CT can provide an assessment of coronary anatomy, including stenosis and anomalous origin of coronary arteries. Disadvantages of CT are the use of radiation and radioiodine contrast and inferior temporal resolution compared with echocardiography. CT angiography is discussed in Section 6.6. Recommendation-Specific Supportive Text
6.5. Heart Rhythm AssessmentSynopsis Both 12-lead electrocardiographic and ambulatory monitoring are necessary for patients with HCM. A 12-lead ECG can convey information about LVH and repolarization abnormalities as well as arrhythmias, including bradycardia and tachycardia. It also provides information about conduction abnormalities that may be present at initial evaluation or in followup. Ambulatory monitoring is necessary in the evaluation for SCD risk. Historically this has been 24 to 48 hours. Extended monitoring is most useful for the determination of the cause of symptoms or to diagnose AF. Recommendation-Specific Supportive Text
6.6. Angiography and Invasive Hemodynamic AssessmentSynopsis Over the past 60 years, the hemodynamic profile and assessment of patients with obstructive HCM has been well established. Echocardiography remains the gold standard for the reliable, noninvasive assessment of dynamic outflow tract obstruction in HCM. For this reason, there is no compelling rationale to consider invasive hemodynamic evaluation in the routine assessment of patients with obstructive HCM or routine coronary angiography in the general population who has HCM. Invasive hemodynamic assessment should be undertaken only when the diagnostic information cannot be obtained from the clinical and noninvasive imaging examinations and when such information will alter patient management. Consequently, selected patient subsets will benefit from these evaluations. It is crucial that the operator who performs the assessment be experienced in such cases and use appropriate catheters while avoiding pitfalls such as catheter entrapment. Recommendation-Specific Supportive Text
6.7. Exercise Stress TestingSynopsis There is evidence to show that exercise stress testing, particularly when combined with simultaneous analysis of respiratory gases (ie, cardiopulmonary exercise test [CPET]), is safe in patients with HCM and provides information on the severity and mechanism of functional limitation. The value of exercise testing in assessing myocardial ischemia is limited because of resting ECG and wall motion abnormalities. Myocardial perfusion imaging using single-photon or positron emission tomography shows perfusion abnormalities in >50% of patients, most of whom have no significant epicardial CAD. Recommendation-Specific Supportive Text
6.8. Genetics and Family ScreeningSynopsis Genetic testing plays an important role in the diagnosis and management of HCM in patients and their families. HCM is inherited as an autosomal dominant trait in most cases, with offspring having a 50% chance of inheriting the same disease-causing genetic variant.3 A discussion about the role of genetic testing is considered a standard part of the clinical engagement of patients with HCM, including appropriate pre- and posttest genetic counseling performed either by a trained cardiac genetic counselor or by someone knowledgeable in the genetics of cardiovascular disease. It is essential to take a multigenerational (preferably at least 3 generations) family history of HCM and suspected SCD events. The importance of potential psychological, social, legal, ethical, and professional implications of having a genetic disease36 should be conveyed. Genetic assessment should ideally be performed in a specialized multidisciplinary HCM center with experience in all aspects of the genetic counseling and testing process.1 Recommendation-Specific Supportive Text
Figure 2. Genetic testing process in HCM. Colors correspond to the Class of Recommendation in Table 2. HCM indicates hypertrophic cardiomyopathy; LB/B, likely benign/benign; LP/P, likely pathogenic or pathogenic; and VUS, variant of unknown significance. 6.9. Genotype-Positive, Phenotype-NegativeSynopsis Genotype-positive, phenotype-negative individuals are those who carry a pathogenic or likely pathogenic HCM-causing variant but are asymptomatic without evidence of LVH on cardiac imaging. These individuals are also described as having preclinical HCM. They need ongoing cardiac surveillance for development of clinical HCM, although the time from genetic diagnosis to clinical HCM varies considerably within and between families.1,5,7 Studies have reported alterations in myocardial strain, LV relaxation abnormalities, myocardial crypts, mitral valve leaflet abnormalities, abnormal trabeculae, myocardial scarring, electrocardiographic abnormalities, and abnormal serum NT-proBNP concentrations even in the absence of LVH.9–12 However, the clinical significance of these subclinical structural and functional abnormalities is unclear and, therefore, treatment decisions are usually not made based on these findings alone. Recommendation Specific Supportive Text
7. SCD Risk Assessment and Prevention7.1. SCD Risk AssessmentSynopsis HCM has been regarded as the most common cause of SCD in young people in North America, a highly visible and devastating complication of this genetic heart disease.1,2,21,22,26–32 Among patients with HCM, younger patients are at higher risk for SCD than older patients.6,26–30,33,34 The 5-year cumulative proportion of SCD events in childhood HCM from diagnosis was 8% to 10% for SCD events in childhood.35,36 There appears to be no sex- or race-based differences in SCD risk.28,29 Over several decades, a multitude of studies have focused on identification of major clinical risk markers that stratify patients according to level of risk to identify high-risk patients who may be candidates for SCD prevention with ICDs.1–22,26–33,37–61 This risk stratification strategy and the penetration of ICDs into clinical practice has substantially reduced disease-related mortality rates.31,32 A predictive risk score is also available that can derive individualized estimated 5-year SCD risk to aid in risk stratification and ICD decision-making in adult patients.2,22 The evolution of SCD risk assessment, including the addition of new risk markers, has resulted in the removal of abnormal blood pressure response to exercise as a routine part of the SCD risk evaluation. The current conventional noninvasive SCD risk markers (Table 7) used to estimate increased risk level in individual patients with HCM, and to identify those patients most likely to benefit from primary prevention ICD therapy,1,26,27,30–32 are based on personal and family history,1,3,5,6 noninvasive testing including echocardiography.1,7–9 ambulatory electrocardiographic monitoring,13,14 and CMR imaging.15–20 Given that the risk of SCD extends over many decades of life, periodic reassessment of SCD risk is an integral component of the longitudinal evaluation of most patients with HCM1,2,6,22,31,32
Risk Stratification Considerations in Pediatric Patients Historically, risk stratification for SCD in children has been based on risk markers derived from adult HCM studies. Several studies suggest that adult risk factors have limited ability to predict SCD in pediatric patients.35,44,46,59,60 More recent collaborative studies suggest some, but not all, of the adult risk factors are important in pediatric patients with HCM.35,54,57,59,60 Risk prediction models for children with HCM have been developed but have not yet been used widely in clinical practice.35,36 The risk factors proposed in these guidelines remain based on adult risk factors and current available pediatric specific information.33,36–64 Ultimately, decisions regarding ICD placement must be based on individual judgment for each patient, taking into account all age-appropriate risk markers, strength of the risk factor(s) identified, the overall clinical profile, the level of risk acceptable to the patient and family, and the potential complications related to device implants, including psychological impact and inappropriate ICD shock. Recommendation-Specific Supportive Text
7.2. Patient Selection for ICD PlacementSynopsis In patients with HCM, risk stratification and selection of patients for prophylactic ICD therapy continues to evolve, including novel risk markers and predictive scoring strategies.1–28,30–34,36 The proven efficacy of the ICD in aborting potentially life-threatening ventricular tachyarrhythmias and saving lives in patients with HCM has placed increasing weight on the importance of accurate selection of patients for device therapy.4,5,28,37 Over the past several decades, retrospective observational studies have identified a number of noninvasive clinical risk markers associated with increased risk for sudden death events in HCM2–28,30–32 In association with clinical judgment and shared decision-making, patients with HCM are considered potential candidates for primary prevention ICDs by virtue of ≥1 major risk markers which, together, have a high sensitivity in predicting those patients with HCM at greatest future risk for sudden death events.1,2,4,37 More recently, other approaches to risk stratification in HCM have emerged. By incorporating a number of disease-related features into a logistic regression equation, a 5-year sudden death risk can be estimated.3,19,29 This risk score in HCM may help patients understand a quantified estimate of their SCD risk that can be used during shared decision-making discussions.3,19 Because individual patients may consider the impact of SCD risk estimates differently, it is the consensus of this committee that prespecified management recommendations should not be assigned to calculated risk estimates as the sole arbiter of the decision to insert an ICD. Contemporary SCD risk markers in HCM, including LV apical aneurysm, LGE, and systolic dysfunction (EF <50%), are not included in the risk calculator, and their impact on the calculated 5-year risk estimate is uncertain. Recommendation-Specific Supportive Text
Figure 3. ICD patient selection. Colors correspond to the Class of Recommendation in Table 2. *ICD decisions in pediatric patients with HCM are based on ≥1 of these major risk factors: family history of HCM SCD, NSVT on ambulatory monitor, massive LVH, and unexplained syncope. †In patients >16 years of age, 5-year risk estimates can be considered to fully inform patients during shared decision-making discussions. ‡It would seem most appropriate to place greater weight on frequent, longer, and faster runs of NSVT. CMR indicates cardiovascular magnetic resonance; EF, ejection fraction; FH, family history; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; LGE, late gadolinium enhancement; LVH, left ventricular hypertrophy; NSVT, nonsustained ventricular tachycardia; SCD, sudden cardiac death; VF, ventricular fibrillation; and VT, ventricular tachycardia. Figure 4. Management of symptoms in patients with HCM. Colors correspond to the Class of Recommendation in Table 2. GL indicates guideline; HCM, hypertrophic cardiomyopathy; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; and SRT, septal reduction therapy. Figure 5. Heart failure algorithm. Colors correspond to the Class of Recommendation in Table 2. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitors; CRT, cardiac resynchronization therapy; EF, ejection fraction; GDMT, guideline-directed management and therapy; HCM, hypertrophic cardiomyopathy; LBBB, left bundle branch block; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; and NYHA, New York Heart Association.
7.3. Device Selection ConsiderationsSynopsis The decision of which type of ICD to implant is very important and nuanced. There are risks and benefits to consider. Considerations include transvenous versus subcutaneous ICD, single-chamber versus dual-chamber versus CRT devices, and number of defibrillation coils when using a transvenous approach. Patients with HCM receiving ICDs are usually younger than those with ischemic and even nonischemic cardiomyopathies who receive a device and, thus, life-long complications are likely to be higher in those with HCM. Pediatric Concerns ICD implantation in children raises additional concerns and challenges.30–32 Although selection for who should receive ICDs is discussed in the preceding section, the approach to implantation will vary based on body size. Epicardial leads will often be necessary in smaller children, usually <30 kg, and for children requiring an LV/CRT lead. Complications of ICDs may be higher in children and adolescents because of higher baseline heart rates, which can lead to inappropriate shocks, somatic growth that increases risk of lead fracture, and the need for multiple device replacements/extractions over a lifetime.30 In younger patients, transvenous leads have shown higher rates of failure compared with older patients. Smaller individuals with subcutaneous ICDs may also be at risk for higher complication rates, including device erosion.31–33 Recommendation-Specific Supportive Text
8. Management of HCM8.1. Management of Symptomatic Patients With Obstructive HCM8.1.1. Pharmacologic Management of Symptomatic Patients With Obstructive HCMSynopsis The principal role of pharmacologic therapy targeted at the dynamic left ventricular obstruction is that of symptom relief, because there are not convincing data to suggest that pharmacologic therapy alters the natural history of HCM. Because the outflow tract obstruction is remarkably variable throughout daily life, the success of a given medication is determined by the patient’s symptom response and not the measured gradient. In general, nonvasodilating beta-blockers are considered first-line therapy. The calcium channel blockers, verapamil, or diltiazem are reasonable alternatives to beta-blocker therapy. For patients who do not respond to trials of ≥1 of these drugs, advanced therapies with disopyramide or septal reduction are often the next step. One of the other key steps in managing symptomatic, obstructive HCM is to eliminate medications that may promote outflow tract obstruction, such as pure vasodilators (eg, dihydropyridine class calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) and high-dose diuretics. Low-dose diuretics, when added to other first-line medications, are sometimes useful for patients with persistent dyspnea or congestive symptoms. The principles of pharmacologic management outlined here also apply to patients with obstruction at the midventricular level. Recommendation-Specific Supportive Text
8.1.2. Invasive Treatment of Symptomatic Patients With Obstructive HCMSynopsis SRT is generally reserved for patients whose symptoms are not relieved by medical therapy and impair quality of life, usually consistent with NYHA functional class III or class IV. Transaortic extended septal myectomy is an appropriate treatment for the broadest range of symptomatic patients with obstructive HCM. Techniques of myectomy have evolved and allow gradient relief at any level of obstruction within the ventricle,28–30 with demonstrated mortality <1% and clinical success >90% to 95%.1,24,31–33 Although some centers achieve these results with isolated extended septal myectomy, other centers have found value in including revision of the anterior mitral leaflet or apparatus.27,34–39 Successful myectomy eliminates or reduces SAM-mediated MR and leads to a reduction in left atrial size and a small degree of LV reverse remodeling.27,31,40,41 Long-term survival after surgical myectomy is similar to an age-matched general population, and recurrent outflow tract obstruction is rare.42–44 Septal myectomy is especially advantageous in patients who have associated cardiac disease requiring surgical correction and in patients with associated papillary muscle abnormalities that contribute to outflow tract obstruction.4,39,45 Similarly, techniques of alcohol septal ablation have been refined, and in centers with experienced interventional teams, procedural mortality is low (<1%). Alcohol septal ablation requires appropriate coronary anatomy, and the procedure may be less effective with high resting gradients (≥100 mm Hg) and extreme septal thickness (≥30 mm).9,46 Earlier concerns regarding late ventricular arrhythmias related to septal scar are not substantiated in more recent series, and intermediate-term survival is generally similar to that of patients who have undergone surgical myectomy.8,9,47,48 Alcohol septal ablation is associated with greater risk of conduction block requiring a permanent pacemaker compared with surgical myectomy and greater need for repeat intervention because of residual obstruction; repeat alcohol septal ablation or myectomy is reported in 7% to 20% of patients after alcohol septal ablation.8–10 Septal reduction by alcohol septal ablation avoids sternotomy and, generally, patients experience less pain. Septal reduction by alcohol septal ablation is advantageous in patients whose frailty or comorbid conditions increase the risk of surgical myectomy. Recommendation-Specific Supportive Text
8.2. Management of Patients With Nonobstructive HCM With Preserved EFSynopsis Symptomatic, nonobstructive HCM is a diagnostic and therapeutic challenge. This is related to differences in disease onset, severity, and risk for adverse outcomes.13 The overall risk for HCM- related death appears similar between patients with and without obstructive physiology.14 Dyspnea and chest discomfort are common symptoms in patients with nonobstructive HCM. These can be a result of increased LV filling pressures related to diastolic dysfunction (including restrictive physiology) or decompensated HF, increased myocardial oxygen demand, impaired microvascular function, or coincidental CAD. The presence of restrictive physiology in association with HCM has been described in children and appears to confer higher risk of adverse outcomes.15 In patients with angina or CAD risk factors, obstructive CAD should be excluded.16 Comorbid conditions including hypertension, diabetes, obesity, and physical inactivity are often major contributors to reduced fitness and symptoms in patients with nonobstructive HCM. Control of these comorbid conditions in combination with pharmacologic therapies for HCM can provide optimal reduction of symptom burden. No trials have prospectively evaluated the long-term outcomes with medications in patients with nonobstructive HCM. Recommendation-Specific Supportive Text
8.3. Management of Patients With HCM and Atrial FibrillationSynopsis AF, commonly observed in patients with HCM, is associated with significant morbidity, impaired quality of life, and substantial stroke risk. Therapy includes prevention of thromboembolic events and controlling symptoms. Traditional stroke risk scoring systems used in the general population are not predictive in patients with HCM. Vitamin K antagonists are effective for stroke prevention, and recent studies support the use of DOACs as well. In view of the substantial stroke risk, periodic AF surveillance would allow for early intervention with anticoagulants in high-risk patients. Asymptomatic AF detected by cardiac devices or monitors also increases risk of stroke, so the decision to anticoagulate should take into considerations the duration of episodes as well as underlying risk factors. When a rhythm control strategy is needed, a number of antiarrhythmic drugs have been shown to be safe and effective, allowing for individualization according to underlying substrate and patient preference. Catheter ablation is also an important option, although the procedure is less effective than in the general population, and there is a more frequent need of repeat procedures and concomitant use of antiarrhythmic drugs. Surgical AF ablation, often with atrial appendage removal, is a potential rhythm management option in patients undergoing surgical myectomy. Surgical AF ablation or maze is not frequently pursued as an isolated surgical indication. Other supraventricular arrhythmias and atrial flutter are likely not increased in incidence in patients with HCM, and treatment is usually similar to populations without HCM. Recommendation-Specific Supportive Text
8.4. Management of Patients With HCM and Ventricular ArrhythmiasSynopsis In patients with HCM and ICDs, preventing recurrent VT is an important goal of therapy, because ICD shocks have been associated with impaired quality of life and worse outcomes.12 Most studies on secondary prevention of VT are extrapolated from studies in patients without HCM because data on VT management in patients with HCM are scant. The choice of pharmacologic therapy should be individualized according to individual substrate, but amiodarone is generally considered superior, albeit at the expense of increased side effects and with no effect on overall survival. Programming ICDs with antitachycardia pacing may minimize risk of shocks because monomorphic VT and ventricular flutter are common. In cases refractory to antiarrhythmic drugs and to optimal ICD programming, catheter ablation is an option. Recommendation-Specific Supportive Text
8.5. Management of Patients With HCM and Advanced HFSynopsis A general approach to the management of heart failure symptoms is shown in Figures 4 and 5. As EF often overestimates myocardial systolic function in patients with HCM, by convention, an EF <50% is associated with worse outcomes, and therefore is considered to represent significantly reduced systolic function. As such, in patients with HCM, guideline-directed medical therapy for heart failure with reduced ejection fraction is initiated for EF <50% (as opposed to <40% in other heart failure populations) and otherwise is generally based on the Heart Failure Guidelines.1,2,22–28 ICD for the primary prevention of SCD, or CRT in patients with EF <50% and NYHA class III to class IV symptoms who meet other criteria for CRT are also used.1 Regardless of LVEF, if patients experience recurrent ventricular arrhythmias or severe (NYHA class III to class IV) symptoms despite optimization of medical therapy and SRT is not an option, heart transplant evaluation is warranted, and CPET plays a role in risk stratification. For patients with NYHA class III to class IV symptoms, an LVAD is sometimes used. Recommendation-Specific Supportive Text
9. Lifestyle Considerations for Patients With HCMTable 9 addresses lifestyle considerations for patients with HCM.
9.1. Sports and ActivitySynopsis Although regular physical activity is well known to promote longevity and to reduce overall cardiovascular disease risk, recommendations for recreational exercise and competitive sports participation for patients with HCM have been challenging.5,6,12,13 Available data provide discordant information regarding the risk of SCD with participation in these activities and the proportion of these SCDs that are attributable to HCM.14–21 Although previous observational studies identify HCM as one of the most common causes of SCD among competitive athletes,14,15 SCD is overall a rare event in young people,17,22 including athletes.18,20,21,23 and in those with a diagnosis of HCM.24,25 Given these somewhat disparate findings and the enormous heterogeneity in HCM disease expression, it is not possible to reliably define for any individual patient with HCM the degree to which risk may be increased by participating in vigorous recreational or competitive sports. For these reasons, evaluation of athletes with HCM should incorporate a shared dialogue, with weight given to individual patient contribution/participation in a discussion balanced with an understanding of the potential risk of SCD associated with physical activity4,26–28 Final decisions for eligibility for competitive sports participation often involve third parties acting on behalf of the schools or teams. Recommendation-Specific Supportive Text
9.2. OccupationSynopsis There are a number of occupational considerations for patients with HCM, particularly when there is potential for loss of consciousness that can place the patient or others in a harmful situation. For some occupations (commercial driving and piloting an aircraft), there are federal guidelines and restrictions that cannot be superseded by this guideline document. Recommendation-Specific Supportive Text
9.3. PregnancySynopsis Pregnancy in most women with HCM is well tolerated. Maternal mortality is very low, with only 3 sudden deaths reported in the literature, all in high-risk (and 1 undiagnosed) patients, over the past 17 years.8–11 Symptoms (dyspnea, chest pain, palpitations) and complications (HF and arrhythmias) occur in ~25% of pregnant women with HCM, for whom most had symptoms preceding their pregnancy. There is no difference in outcomes reported for women with LVOTO compared with those without obstruction. Recommendation-Specific Supportive Text
9.4. ComorbiditiesSynopsis Comorbid conditions, including hypertension, obesity, and sleep-disordered breathing, are common in patients with HCM and may contribute to increased symptom burden, LVOTO, HF, and AF. Appropriate counseling and management of these conditions in patients with HCM is a critical component of their care. Recommendation-Specific Supportive Text
10. Unmet Needs10.1. Limitations and Knowledge Gaps10.1.1. Clinical TrialsThere have been few clinical trials, particularly RCTs, in HCM. Thus, many of the recommendations put forth in this guideline are based on data from observational studies or expert opinion. More data are needed to identify strategies to improve functional capacity (particularly in symptomatic patients with nonobstructive HCM), to attenuate disease progression, and to reduce adverse outcomes. RCTs are challenging in this population, because of very low overall event rates and a slow rate of disease progression in most patients. As such, there is a clear need for novel trial designs and specific patient-reported outcome tools to rigorously assess impact of new therapies on meaningful endpoints, including quality of life- and sex-based differences among patients with HCM. 10.1.2. Prevent or Attenuate Disease ProgressionThere are currently no known preventive or disease-modifying therapies for HCM, in large part because of insufficient knowledge of the underlying biology that leads to disease emergence and progression. In a small RCT, diltiazem stabilized LV wall thickness: dimension ratio in gene variant carriers without LVH and decreased LV mass and diastolic filling in a subgroup.1 Valsartan is currently being tested for its potential to attenuate disease progression in young gene variant carriers without LVH and in those with early manifestations of HCM.2 Gene editing of underlying causal gene variants using technologies such as CRISPR/Cas9, gene replacement therapy, and allele-specific silencing are being investigated in preclinical studies, but are of uncertain clinical applicability at this time given unknown efficacy and concerns for off-target effects or toxicity. 10.1.3. Reduce Symptom Burden and Increase Functional Capacity, Particularly in Nonobstructive HCMAlthough beta-blockers and non-dihydropyridine calcium channel blockers are the mainstay of medical therapy for patients with HCM, their use is largely empiric and predicated on a small number of studies. Other drugs that have been tested in RCTs in patients with HCM have not shown a benefit, demonstrated toxicity, or a signal for harm.3–5 An open-label, nonrandomized phase 2 trial of a small-molecule inhibitor of myosin showed decreased post-exercise LVOT gradients, improved exercise capacity, and lowered dyspnea scores.6 This is now being investigated in a phase 3 RCT.7 In patients with nonobstructive HCM, a phase 2 trial showed that treatment with the myosin inhibitor was associated with a reduction in NT-proBNP.8 Ongoing clinical trials are testing myosin inhibitors for efficacy in improving functional capacity in patients with both obstructive and nonobstructive HCM. Clinical trials that test lifestyle interventions to reduce symptom burden are also needed. Given the benefits of cardiopulmonary rehabilitation in other cardiac diseases, adding HCM to the list of reimbursable diagnoses would extend these benefits to this population. 10.1.4. Risk StratificationDespite several large, prospective studies examining risk predictors of SCD, risk stratification algorithms still have low positive-predictive values such that many ICDs are placed unnecessarily. On the other hand, sudden cardiac arrest or SCD occurs in patients with no established risk factors, albeit rare. New risk factors and tools to enhance the power of risk stratification algorithms are needed, particularly in children. Similarly, the ability to predict which patients with HCM will suffer other adverse outcomes, such as HF and AF, is limited. These questions will benefit from continued assembly and growth of large, prospective registries that track clinical outcomes in well-genotyped and -phenotyped patients with HCM. Studies including larger numbers of pediatric and non-White populations with HCM are particularly needed. 10.1.5. Arrhythmia ManagementAF affects a large proportion of adult patients with HCM, is often poorly tolerated, and may be more refractory to pharmacologic and catheter-based interventions than in patients without HCM.9–13 Technical advances in ablative therapy for AF may increase the success rate in patients with HCM.14 Prevention and treatment of ventricular arrhythmias in patients with ICDs and HCM can be problematic for a number of reasons. They include the often-young age at implantation and need for lifelong generator and lead revisions and high rate of inappropriate shocks for sinus tachycardia and atrial arrhythmias. Advances in device technology, arrhythmia discrimination, and treatment algorithms may be of benefit to this population. 10.1.6. GeneticsGenetic testing services are not widely available outside of experienced centers. Greater access to genetic counseling and testing is needed for all patients with HCM. Improved algorithms for the interpretation of variants that are currently classified as variants of uncertain significance are also necessary. This will be greatly facilitated by efforts from the Clinical Genome Resource (ClinGen), a funded resource of the National Institutes of Health, in expert variant curation (https://clinicalgenome.org/).15 Approximately 50% of cases of HCM are genetically elusive. New gene discovery is needed to identify additional causal genes, recognizing that many of these cases may result from a combination of polygenic variants and environmental factors. Investigation into the phenotypic associations and clinical outcomes associated with individual variants should continue as well. 10.1.7. Exercise and Sports ParticipationData regarding potential risks of sports participation for patients with HCM are limited. Although this guideline document introduces the concept of a shared discussion regarding sports participation, more data are needed to frame these discussions and to inform patient decisions. A prospective, multicenter observational study to determine how exercise practices (including vigorous and competitive sports) impact patient outcomes and quality of life is ongoing. A randomized trial comparing the efficacy of high-intensity exercise versus moderate-intensity exercise to improve cardiorespiratory fitness and diastolic reserve in patients with HCM is also underway. ACC/AHA Joint Committee MembersPatrick T. O’Gara, MD, MACC, FAHA, Chair; Joshua A. Beckman, MD, MS, FAHA, Chair-Elect; Glenn N. Levine, MD, FACC, FAHA, Immediate Past Chair*; Sana M. Al-Khatib, MD, MHS, FACC, FAHA*; Anastasia Armbruster, PharmD, AACC; Kim K. Birtcher, PharmD, MS, AACC; Joaquin Ciggaroa, MD, FACC*; Dave L. Dixon, PharmD, FACC; Lisa de las Fuentes, MD, MS, FAHA, FASE; Anita Deswal, MD, MPH, FACC, FAHA; Lee A. Fleisher, MD, FACC, FAHA*; Federico Gentile, MD, FACC*; Zachary D. Goldberger, MD, MSc, FACC, FAHA; Bulent Gorenek, MD, FACC; Norrisa Haynes, MD, MPH; Adrian F. Hernandez, MD, MHS; Mark A. Hlatky, MD, FACC, FAHA*; José A. Joglar, MD, FACC, FAHA; W. Schuyler Jones, MD, FACC; Joseph E. Marine, MD, FACC*; Daniel Mark, MD, MPH, FACC, FAHA; Latha Palaniappan, MD, MS, FAHA, FACC; Mariann R. Piano, RN, PhD, FAHA; Jacqueline Tamis-Holland, MD, FACC; Duminda N. Wijeysundera, MD, PhD*; Y. Joseph Woo, MD, FACC, FAHA Presidents and StaffAmerican College of CardiologyAthena Poppas, MD, FACC, President Cathleen Gates, Interim Chief Executive Officer John S. Rumsfeld, MD, PhD, FACC, Chief Science and Quality Officer MaryAnne Elma, MPH, Senior Director, Science, Education, Quality, and Publishing Grace D. Ronan, Team Lead, Clinical Policy Publications Timothy W. Schutt, MA, Clinical Policy Analyst American College of Cardiology/American Heart AssociationThomas S. D. Getchius, Director, Guideline Strategy and Operations Abdul R. Abdullah, MD, Director, Guideline Science and Methodology Laura Mitchell, Guideline Advisor American Heart AssociationMitchell S.V. Elkind, MD, MS, FAAN, FAHA, President Nancy Brown, Chief Executive Officer Mariell Jessup, MD, FAHA, Chief Science and Medical Officer Radhika Rajgopal Singh, PhD, Vice President, Office of Science, Medicine and Health Anne Leonard, MPH, RN, FAHA, CCRC, Senior Science and Medicine Advisor, Office of Science, Medicine and Health Jody Hundley, Production and Operations Manager, Scientific Publications, Office of Science Operations *Former Joint Committee on Clinical Practice Guidelines member; current member during the writing effort. Footnoteshttps://www.ahajournals.org/journal/circ The American Heart Association requests that this document be cited as follows: Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142:e558–e631. doi: 10.1161/CIR.0000000000000937 Developed in collaboration with and endorsed by the American Association for Thoracic Surgery, American Society of Echocardiography, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society for Cardiovascular Magnetic Resonance. Endorsed by The Pediatric & Congenital Electrophysiology Society ACC/AHA Joint Committee Members, see page e608 This document was approved by the American College of Cardiology Clinical Policy Approval Committee in August 2020, the American Heart Association Science Advisory and Coordinating Committee in August 2020, and the American Heart Association Executive Committee in October 2020. Supplemental materials are available with this article at https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000937 This article has been copublished in the Journal of the American College of Cardiology. Copies: This document is available on the websites of the American College of Cardiology (www.acc.org) and the American Heart Association (professional.heart.org). A copy of the document is also available at https://professional.heart.org/statements by selecting the “Guidelines & Statements” button. To purchase additional reprints, call 215-356-2721 or email Meredith.[email protected]com. The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit https://professional.heart.org/statements. Select the “Guidelines & Statements” drop-down menu near the top of the webpage, then click “Publication Development.” Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at https://www.heart.org/permissions. A link to the “Copyright Permissions Request Form” appears in the second paragraph (https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form). References
1.5. Class of Recommendations 2. Definition, Etiology, Clinical Course, and Natural History 2.2. Nomenclature/Differential Diagnosis 2.3. Definition, Clinical Diagnosis, and Phenotype 2.5. Natural History/Clinical Course 3.2. Diastolic Dysfunction 3.3. Mitral Regurgitation 3.5. Autonomic Dysfunction 4. Shared Decision-Making 5. Multidisciplinary HCM Centers 6. Diagnosis, Initial Evaluation, and Follow-up 6.3. Cardiovascular Magnetic Resonance Imaging 6.4. Cardiac Computed Tomography 6.5. Heart Rhythm Assessment 6.6. Angiography and Invasive Hemodynamic Assessment 6.7. Exercise Stress Testing 6.8. Genetics and Family Screening 6.9. Genotype-Positive, Phenotype-Negative 7. SCD Risk Assessment and Prevention 7.2. Patient Selection for ICD Placement 7.3. Device Selection Considerations 8.1.2. Invasive Treatment of Symptomatic Patients With Obstructive HCM 8.2. Management of Patients With Nonobstructive HCM With Preserved EF 8.3. Management of Patients With HCM and Atrial Fibrillation 8.4. Management of Patients With HCM and Ventricular Arrhythmias 8.5. Management of Patients With HCM and Advanced HF 9. Lifestyle Considerations for Patients With HCM Appendix 1.
Appendix 2.
|